波罗样类激酶1促进肺高血压
Rongrong Chen1, Hongfei Wang2, Cuiting Zheng1,3
1State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
波罗样酶1 (PLK1) 在低氧状态下驱动肺高血压 (PH) 的发展. 抑制PLK1显示出治疗这种致命的血管疾病的前景.
科学领域:
- 心血管研究研究心血管研究
- 肺部医学 肺部医学
- 细胞生物学 细胞生物学
背景情况:
- 肺高血压 (PH) 是一种严重的血管疾病,治疗方法很少.
- 膜缺氧和PH病原体之间的联系仍然不清楚.
- 作为细胞分裂调节剂的Polo样酶1 (PLK1) 正在研究其在PH中的作用.
研究的目的:
- 探索Polo样酶1 (PLK1) 在肺高血压 (PH) 的发展中的作用.
- 了解缺氧和PH之间的机械联系.
主要方法:
- 在低氧条件下研究了小鼠肺部和人类细胞中的PLK1表达.
- 在使用低氧或Sugen5416/低氧的小鼠中诱导PH.
- 使用异构卵性Plk1淘汰赛小鼠和PLK1抑制剂 (BI 2536,BI 6727) 来评估PLK1的意义.
主要成果:
- 缺氧通过HIF1α和RELA增加了PLK1的表达.
- 缺少一个Plk1基因副本的小鼠对缺氧诱导的PH表现出部分抵抗力.
- 在小鼠中,PLK1抑制剂有效降低了PH严重程度.
结论:
- 升高的PLK1对PH发育至关重要.
- PLK1代表了肺高血压的潜在治疗标.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...


